Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: J Clin Pharmacol. 2020 May 20;60(10):1385–1396. doi: 10.1002/jcph.1632

Table 5.

Parameter estimates of the population E-R analysis on exploratory PD biomarkers

Parameter (Unit) Estimates (RSE%)
CD23 MDC/CCL22 IL22BP LTα1/β2 IGFBP-2 MMP12
Emax 0.295 (22.3) 0.339 (18.7) 0.391 (11.3) 0.328 (18.8) 0.372 (44.4) 0.512 (10.4)
E50 (ng∙hr/mL) 1340 (62.4) 1600 (18.3) 1420 (13.9) 1260 (34.9) 260 (183.8) 1200 (11.2)
E0 (RFU) 8880 (3.8) 2420 (3.4) 6790 (3.5) 517 (2.9) 891 (5.6) 3450 (5.3)
γ 5 (Fixed) 5 (Fixed) 4.59 (39) 4.8 (74) 1 (Fixed) 5 (Fixed)
Between-subject variability CV% (RSE%)
ω2E0 20.6 (12.1) 19.2 (12.0) 19.1 (16.8) 11.2 (25.0) 28.5 (13.6) 26.4 (13.3)
Residual variability CV% (RSE%)
σ2prop 11.9 (11.1) 14.5 (11.1) 11.7 (10) 16.9 (10) 17.8 (11.6) 16.9 (9.5)

Abbreviations: σ2prop = variance of proportional random residual effects.